{
  "name": "Ascendis Pharma A/S",
  "ticker": "ASND",
  "headquarters": "Not specified",
  "website": "https://investors.ascendispharma.com/",
  "description": "Ascendis Pharma is a leading biopharma company focused on endocrinology rare diseases using their TransCon technology platform. The company has three approved medicines for hypoparathyroidism and growth disorders, with aspirations to drive >\u20ac5B annual revenue by 2030.",
  "modalities": [
    "TransCon prodrug platform technology"
  ],
  "therapeutic_focus": [
    "Endocrinology Rare Diseases",
    "Growth Disorders",
    "Hypoparathyroidism",
    "Oncology",
    "Ophthalmology",
    "Obesity and Metabolic"
  ],
  "cash_runway": "Expected operating cash flow of ~\u20ac500 million in 2026",
  "partnerships": [
    {
      "partner": "Novo Nordisk",
      "asset": "TransCon semaglutide and other obesity/metabolic products",
      "deal_value": "Exclusive global rights, multi-product collaboration",
      "status": "Active",
      "source_page": 26
    },
    {
      "partner": "Eyconis",
      "asset": "TransCon-based ophthalmology products",
      "deal_value": "$150 million commitment from external investors",
      "status": "Active",
      "source_page": 26
    },
    {
      "partner": "Teijin",
      "asset": "TransCon hGH, TransCon PTH, TransCon CNP in Japan",
      "deal_value": "Exclusive rights",
      "status": "Active",
      "source_page": 26
    },
    {
      "partner": "VISEN Pharmaceuticals",
      "asset": "TransCon hGH, TransCon PTH, TransCon CNP in Greater China",
      "deal_value": "Exclusive rights",
      "status": "Active",
      "source_page": 26
    }
  ],
  "investment_thesis": [
    "Becoming a leading biopharma company with three approved endocrinology rare disease medicines showing strong revenue growth",
    "Vision 2030 to achieve >\u20ac5B annual revenue with multiple blockbuster products",
    "Q4 2025 product revenue of ~\u20ac240 million and FY 2025 product revenue of ~\u20ac683 million demonstrating commercial execution",
    "TransCon platform enables continuous flow of highly differentiated products with new composition of matter patents",
    "TransCon CNP is the only achondroplasia treatment to show benefits beyond height compared to placebo in pivotal trial",
    "Strong cash position with \u20ac616 million and expected operating cash flow of ~\u20ac500 million in 2026"
  ],
  "key_risks": [
    "Forward-looking statements subject to significant uncertainties and risks that could cause actual results to differ materially",
    "Investigational products limited by law to investigational use with no representations made as to safety or effectiveness",
    "Regulatory approval timing and success not guaranteed for pipeline assets"
  ],
  "_source_pages": [
    1,
    3,
    4,
    30
  ],
  "_extracted_at": "2026-02-04T13:33:12.097927",
  "_last_extracted": "2026-02-04T13:33:12.098516"
}